Financials data is unavailable for this security.
View more
Year on year YiChang HEC ChangJiang Pharmaceutical Co Ltd grew revenues 68.08% from 3.74bn to 6.29bn while net income improved 2,501.23% from 76.60m to 1.99bn.
| Gross margin | 78.90% |
|---|---|
| Net profit margin | 27.37% |
| Operating margin | 32.91% |
| Return on assets | 11.69% |
|---|---|
| Return on equity | 21.15% |
| Return on investment | 17.27% |
More ▼
Cash flow in CNYView more
In 2023, YiChang HEC ChangJiang Pharmaceutical Co Ltd increased its cash reserves by 81.30%, or 750.87m. The company earned 1.67bn from its operations for a Cash Flow Margin of 26.58%. In addition the company generated 554.57m cash from investing, though they paid out 1.48bn more in financing than they received.
| Cash flow per share | 2.39 |
|---|---|
| Price/Cash flow per share | 3.42 |
| Book value per share | 10.84 |
|---|---|
| Tangible book value per share | 7.63 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.15 |
|---|---|
| Quick ratio | 1.93 |
| Total debt/total equity | 0.270 |
|---|---|
| Total debt/total capital | 0.2126 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 2,501.30%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| Div yield(5 year avg) | 0.91% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | 16.78 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 44.69 |
More ▼
